Clinical Trial Update: Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

View source ↗

Summary

This is a completed clinical trial update evaluating deferasirox for transfusional hemosiderosis, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusional Hemosiderosis

Drugs mentioned

• Exjade (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusional Hemosiderosis | Status: COMPLETED